literature

HIV mutation literature information.

Surveillance of Pretreatment Drug Resistance Among HIV-Infected Children in Ibadan, Nigeria.

PMID: 34074135 2021 AIDS research and human retroviruses

Abstract: Three out of the four mutations were identified as non-nucleoside reverse transcriptase inhibitors DRM (K103N), whereas the fourth had nucleoside reverse transcriptase inhibitors DRM (M184V).

Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.

PMID: 33855355 2021 The Journal of antimicrobial chemotherapy

Abstract: Resuming the same 2-DR 7 days a week led to viral resuppression in three patients, whereas the M184V mutation emerged in one patient, leading to ART modification.

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.

PMID: 33941212 2021 AIDS research and therapy

Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.

Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.

Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.

High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.

PMID: 34025122 2021 Infectious diseases

Abstract: Of the 27 viraemic isolates successfully genotyped, 20 (74.1%) carried DR mutations; most frequent were M184VI (55.6%), K103N (37.1%), thymidine analog mutations (29.6%), Y181CY (22.2%).

Result: FTC and 3TC were also predicted with high-level DR (55.6%), which however is associated with a higher fitness cost due to the point mutation M184V.

Result: For NRTIs, these were M184VI (55.6%), T215SNY (22.2%), and K65R (18.5%).

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

PMID: 34064774 2021 Viruses

Result: Five SDRMs increased in prevalence among NRTI-experienced persons including K65R, K70E, Y115F, and M184V/I.

Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.

PMID: 34069929 2021 International journal of molecular sciences

Result: The most common SDRM (Figure 1, Supplementary Table S2) were the substitutions in RT amino acids M184V (65.53%, n = 13,265), K103N (40.20%, n = 8738), and M41L (17.21%, n = 3480).

Result: The most common mutation across the years was M184V (Figure 1), notwithstanding a decreasing trend and a significant decrease between 2015 (68.29%, n = 1874) and 2016 (53.21%, n = 2684) (p < 0.001) (Table 2).

Discussion: Along with the most common mutations, M184V rates presented a decrease over the yrs (76.88% in 2008 to 51.48% in 2017).

Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.

PMID: 34189182 2021 Open forum infectious diseases

Abstract: We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.

Discussion: Neither the M184V (RT) mutation nor the R263KR (INI) mutation was observed in the 2 pretreatment genotypes, suggesting that these were treatment-emergent mutations and were not transmitted or present at baseline.

Discussion: The M184V (RT) mutation was detected after 17 weeks of therapy, and at week 37 the R263KR (INI) mutation was detected via bulk sequencing (Viracor Lab, Missouri) necessitating a change in ART.

High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.

PMID: 34212033 2021 BioMed research international

Abstract: The DRMs most frequent were M184I/V (82.9%) for nucleoside reverse transcriptase inhibitors (NRTI), K103N/S (63.4%) for nonnucleoside reverse transcriptase inhibitor (NNRTI), and V82A/L/M (7.3%) for protease inhibitors (PI).

Discussion: An elevated frequency of M184V (75%) was also detected herein, as well as in the study conducted in Belem; this has ranged from 54.4% in Sao Paulo to 81.2% in Bahia.

Discussion: Despite the low impact of the M184V alone to NRTI resistance, when taken together to other

Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016.

PMID: 34195923 2021 Archives of virology

Abstract: The most frequent mutation was M46L (58, 0.89%), followed by K103N (36, 0.55%), M46I (36, 0.55%), and M184V (26, 0.40%).

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

PMID: 33806576 2021 Viruses

Abstract: In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSFWT and HIV-1 JR-CSFK65R_M184V.

Result: Furthermore, HIV-1 JR-CSFWT replicates at a higher efficiency when compared to the replication kinetics of HIV-1 JR-CSFK65R_M184V (Figure 3D,E).

Result: HIV-1 JR-CSFK65R_M184V replicated more than 3-logs lower than HIV-1 JR-CSFWT.

Browser Board

Co-occurred Entities

Filtrator